Compare TILE & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | NUVB |
|---|---|---|
| Founded | 1973 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | TILE | NUVB |
|---|---|---|
| Price | $31.32 | $4.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $36.00 | $11.38 |
| AVG Volume (30 Days) | 513.1K | ★ 4.4M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,386,854,000.00 | N/A |
| Revenue This Year | $6.72 | $203.82 |
| Revenue Next Year | $5.61 | $58.18 |
| P/E Ratio | $76.00 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $20.01 | $1.57 |
| 52 Week High | $35.11 | $9.75 |
| Indicator | TILE | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 62.06 | 50.71 |
| Support Level | $26.70 | $4.07 |
| Resistance Level | $32.15 | $5.16 |
| Average True Range (ATR) | 0.95 | 0.36 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 83.43 | 28.15 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.